Ann: Phase 3 Trial in COVID-19 ARDS Surpasses 50% Enrollment, page-236

This post from @@conman84 contains misinformation. The results of the trial are blinded, there's no way to know anything until a result comes out, and I modeled the results of the trial vs different survival rates in the control arm and overwhelming efficacy wasn't achieved until the 45% readout at the earliest, but more likely at the 60% readout. So again, everything you wrote is misleading, either intentionally or in good faith.

Thanks @Stickshift that's what I had read too.

I guess it comes down to whether Sinai are acting under greater directive from the NIH or from MSB for the trial, and then what the arrangement is on approval, and also the confidence MSB has in FDA approval. The points above about funding are good ones too, so hopefully the FDA have been clear about what they need for approval and the trial proceeds to that endpoint based on the observed results.